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Type 2 diabetesCorrespondence
Dear Sir,
Maturity Onset Diabetes of the Young (MODY; MIM#
606391) represents a genetically and clinically heteroge-
neous form of diabetes mellitus (DM) [1-3], characterized
by hyperglycaemia or overt diabetes, in at least two or three
consecutive generations, onset <25 years of age, absence of
anti ß-cells antibodies. Loss-of-function HNF4A mutations
cause a progressive loss of ß-cell function [4] and, eventu-
ally, frank hyperglycaemia denominated as MODY1.
HNF4A mutations have been associated with MODY1, type
2 diabetes and gestational diabetes (GDM) [5].
Findings
We describe a 10 years old diabetic girl recruited within
a sample of MODY patients [6], Personal history: she is
the first of two children born from non-consanguineous
parents and was born full term and appropriate for gesta-
tional age after a pregnancy complicated by GDM. No
transient congenital hyperinsulinism was detected [7]. She
was healthy until the age of 9.1 years, when she was admit-
ted to the local Hospital because of fainting. At admission,
the following was recorded: blood glucose of 200 mg/dl;
blood pressure, fundus oculi, heart ultrasound, electrocar-
diogram, blood biochemistry and pH were all normal; anti-
thyroid and anti ß-cells antibodies were negative; finally,
oral glucose tolerance test (OGTT) was consistent with
DM (Table 1), with reduced insulin production (Matsuda* Correspondence: mdelvecchio75@gmail.com
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article, unless otherwise stated.Index 17.18, HOMA-IR 0.98, Insulinogenic Index −0.02,
Disposition Index 0). Familial history was as follows:
40 years old healthy father; 35 years old mother, diagnosed
as having GDM in both pregnancies (during pregnancies
fasting blood glucose ranging from 110 to 140 mg/dl,
blood glucose at 120′ of OGTT 597 mg/dl and 403 during
the first and the second pregnancy, respectively); a 6 years
old healthy brother; maternal grandmother and one out of
2 maternal uncles with type 2 DM which was diagnosed
when he was 30 years old.
At admission, two IU of regular insulin at lunch and at
dinner and a hypocaloric diet (BMI 24.1 kg/m2, 95th cen-
tile) were started. Three weeks later, body weight had
dropped 1 kg and insulin injections were stopped because
of recurrent hypoglycaemias. The patient was referred to
our Unit 5 months later, still off of insulin. At that time,
HbA1c was 40 mmol/mol and BMI 19.4 kg/m2 (75th cen-
tile). The HNF4A (NM_175914.4) gene analysis by PCR
followed by direct sequencing showed the p.R311H
c.932G >A variation in exon 8 (previously reported as p.
R323H [8]). This mutation resides in the highly conserved
extreme carboxy terminal domain [9] and causes a semi-
conservative aminoacid substitution predicted to be prob-
ably damaging by The Human Gene Mutation Database
(http://www.hgmd.org) [10] and by PolyPhen-2 tool [11].
Genetic analysis was carried out also in first-degree
relatives and in the maternal uncles, showing the same
mutation in the mother, the brother, and the diabetic
uncle. They underwent a comprehensive laboratory evalu-
ation (Table 1). When 7.9 year-old, the brother underwent
further examination showing impaired glucose tolerance
(IGT) (baseline and after 120′ blood glucose and insulin:tral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/4.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
Table 1 The table shows clinical and biochemistry data of the proband at DM diagnosis in the upper part and data at
last examination of all mutation carriers (including proband) in the lower part
Proband’s data at the time of clinical diagnosis of DM (i.e. at age of 9.1 years)
HbA1c (mmol/mol) 58
C-peptide (ng/ml) 2.9
Total/HDL cholesterol (mg/dl) 176 / 34
Triglycerides (mg/dl) 105
Systolic/diastolic blood pressure (mmHg) 113 / 65
Fundus oculi Normal
Anti-thyroid, ICA, GAD, IA-2 antigens antibodies Negative
Oral glucose tolerance test Blood glucose (mg/dl) Blood insulin (microU/ml)
Before glucose load 100 10.4
30 min after glucose load 215 57.2
60 min after glucose load 308 82.2
90 min after glucose load 351 84.3
120 min after glucose load 320 77.7
Clinical data Proband Brother Mother Uncle
Age at examination (yrs) 10.7 8 36.5 33.1
Age at diagnosis (yrs) 9.1 7.2 26 30.2
Glycaemic status diagnosed Transient DM IGT GDM DM
Age at genetic testing (yrs) 9.6 7.2 35.9 32.5
BMI (Kg/m2) 19 19.5 20.9 26.3
Blood pressure (mmHg) 107 / 68 110 / 60 160 / 90 130 / 80
HbA1c (mmol/mol) 6.1 37 40 60
Fasting blood glucose (mg/dl) 99 72 80 171
C-peptide (ng/ml) 1.9 1.3 1.1 1.4
Insulin (microU/ml) 7.6 3.5 3 4.3
Total cholesterol (mg/dl) 157 126 152 177
HDL cholesterol (mg/dl) 57 35 55 50
LDL cholesterol (mg/dl) 80 77 83.8 118
Triglycerides (mg/dl) 59 54 66 45
Creatinine (mg/dl) 0.45 0.59 0.67 0.89
Albuminuria (mg/dl) 7 8.4 3 8.2
Glycosuria (mg/dl) Absent Absent Absent Absent
Anti-hyperglycaemic therapy None None Diet, physical activity Diet, physical activity
Fundus oculi Normal Normal Normal Normal
DM: diabetes mellitus. IGT: impaired glucose tolerance at OGTT. GDM: gestational diabetes mellitus.
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insulin production (Matsuda Index 28.56, HOMA-IR 0.77,
Insulinogenic Index −0.05, Disposition Index 0), HbA1c
39 mmol/mol, and BMI 20.4 kg/m2 (90th centile).
Conclusions
HNF4A mutations lead to a progressive decrease of
insulin secretion and hyperglycaemia [12] requiring
oral hypoglycaemic drugs or insulin in most cases[13]. Our proband required low insulin dose (0.09 IU/
kg/day) only for few weeks. This transient course is
puzzling and never described in HNF4A-MODY chil-
dren so far. Likely, in the weeks before the diagnosis,
some triggering factors played a role in deteriorating
glucose homeostasis. As she became normoglycaemic
and insulin free after some weight lost, we suggest that
overweight may have played a major role, but we cannot
exclude the role of other concomitant factors (stress or
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on normocaloric diet and presents a good glycaemic con-
trol (HbA1c 40 mmol/mol) without any hypoglycaemic
treatment.
We did not perform any molecular study showing the ef-
fect of the mutation, so no direct effect can be postulated.
However, we show that it segregates with hyperglycaemia,
as it was found in the mother (GDM, currently normogly-
caemic and normal weight), in the maternal uncle (type 2
DM onset at 30 years of age, currently overweight, diabetic
and on hypoglycaemic diet), and in the brother (IGT). The
same mutation was previously described in a 46 year-old
obese man with type 2 DM and nephropathy [8]. Later, in
the same position, a mutation with Arginine replaced by
Cysteine (previously reported as p.R324C), was described
in a 13 year-old Japanese MODY patient [14]. Unfortu-
nately, no information about the families were reported in
both cases, making impossible to speculate about any role
of HNF4A-R311H on glucose homeostasis. To better as-
sess its pathogenic role, we screened 198 non-diabetic indi-
viduals and 138 type 2 DM patients without family history
of autosomal dominant inheritance of hyperglycaemia /
diabetes and negative data were obtained.
The in silico analysis suggests that the R311H mutation
causes a semiconservative aminoacid substitution pre-
dicted to be probably damaging [10,11]. Since some stud-
ies indicates a neutral [15], and others a deleterious [16]
effect of such variation on HNF4A transcriptional activity,
its biological role is controversial.
In conclusion, we report on a family with the HNF4A-
R311H mutation cosegregating with heterogeneous pheno-
type of abnormal glucose homeostasis, including MODY1.
The lack of a clear genotype-phenotype association re-
quires great caution before considering this mutation
causative of MODY1. We suggest that also transient DM
warrants the screening for MODY in the presence of indi-
cative family history, even if with clinical heterogeneity of
abnormal glucose homeostasis.
Consent
Informed consent was obtained from the patient's par-
ents for publication of this case report.
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